KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Capital Expenditures (2016 - 2025)

BeOne Medicines (ONC) has disclosed Capital Expenditures for 11 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 204.46% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.3 million, a 325.45% increase, with the full-year FY2025 number at $57.3 million, down 18.53% from a year prior.
  • Capital Expenditures was $5.2 million for Q4 2025 at BeOne Medicines, up from -$5.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $309.5 million in Q3 2023 to a low of -$94.8 million in Q4 2021.
  • A 5-year average of $50.6 million and a median of $31.1 million in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: crashed 373.19% in 2021, then surged 770.21% in 2022.
  • BeOne Medicines' Capital Expenditures stood at -$94.8 million in 2021, then soared by 228.06% to $121.4 million in 2022, then increased by 29.34% to $157.0 million in 2023, then plummeted by 103.19% to -$5.0 million in 2024, then surged by 204.46% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Capital Expenditures are $5.2 million (Q4 2025), -$5.9 million (Q3 2025), and -$2.1 million (Q2 2025).